Human prostate cancer progression models and therapeutic intervention

L. W.K. Chung, Chinghai Kao, R. A. Sikes, H. E. Zhau

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Our laboratory has developed two cellular models of human prostate cancer progression. The LNCaP prostate cancer progression model is based upon the wellknown cellular interaction between human prostate or bone stromal cells and LNCaP cells in vivo. The marginally tumorigenic LNCaP cells acquired tumorigenic and metastatic potential upon cellular interaction with either prostate or bone fibroblasts. A subline termed C4-2 was observed to grow readily in castrated animals and acquired metastatic potential spreading from the primary tumor site to the lymph node, the seminal vesicles, and the axial skeleton, resulting in an intense osteoblastic reaction. The second model is ARCaP, where prostate cancer cells derived from the ascites fluid of a man with metastatic disease exhibited an Androgen- and estrogen-Repressed Prostate Cancer cell growth and tumor formation in either a hormone-deficient or a castrated environment. However, the growth of either the tumor cells in vitro or the tumors in vivo was suppressed by both estrogen and androgen. While the tumor cells expressed low levels of androgen receptor and prostate-specific antigen (PSA), they were highly metastatic when inoculated orthotopically. Distant metastases to a number of organs were detected including the liver, lung, kidney, and bone.

Original languageEnglish (US)
Title of host publicationMolecular Biology of Prostate Cancer
Publisherde Gruyter
Pages107-114
Number of pages8
ISBN (Electronic)9783110807271
ISBN (Print)3110161591, 9783110161595
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Neoplasms
Bone and Bones
Androgens
Prostate
Estrogens
Therapeutics
Seminal Vesicles
Androgen Receptors
Prostate-Specific Antigen
Stromal Cells
Growth
Ascites
Skeleton
Fibroblasts
Lymph Nodes
Hormones
Neoplasm Metastasis
Kidney
Lung

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chung, L. W. K., Kao, C., Sikes, R. A., & Zhau, H. E. (2013). Human prostate cancer progression models and therapeutic intervention. In Molecular Biology of Prostate Cancer (pp. 107-114). de Gruyter. https://doi.org/10.1515/9783110807271.107

Human prostate cancer progression models and therapeutic intervention. / Chung, L. W.K.; Kao, Chinghai; Sikes, R. A.; Zhau, H. E.

Molecular Biology of Prostate Cancer. de Gruyter, 2013. p. 107-114.

Research output: Chapter in Book/Report/Conference proceedingChapter

Chung, LWK, Kao, C, Sikes, RA & Zhau, HE 2013, Human prostate cancer progression models and therapeutic intervention. in Molecular Biology of Prostate Cancer. de Gruyter, pp. 107-114. https://doi.org/10.1515/9783110807271.107
Chung LWK, Kao C, Sikes RA, Zhau HE. Human prostate cancer progression models and therapeutic intervention. In Molecular Biology of Prostate Cancer. de Gruyter. 2013. p. 107-114 https://doi.org/10.1515/9783110807271.107
Chung, L. W.K. ; Kao, Chinghai ; Sikes, R. A. ; Zhau, H. E. / Human prostate cancer progression models and therapeutic intervention. Molecular Biology of Prostate Cancer. de Gruyter, 2013. pp. 107-114
@inbook{7854c507abe3489aa115e384180f65c8,
title = "Human prostate cancer progression models and therapeutic intervention",
abstract = "Our laboratory has developed two cellular models of human prostate cancer progression. The LNCaP prostate cancer progression model is based upon the wellknown cellular interaction between human prostate or bone stromal cells and LNCaP cells in vivo. The marginally tumorigenic LNCaP cells acquired tumorigenic and metastatic potential upon cellular interaction with either prostate or bone fibroblasts. A subline termed C4-2 was observed to grow readily in castrated animals and acquired metastatic potential spreading from the primary tumor site to the lymph node, the seminal vesicles, and the axial skeleton, resulting in an intense osteoblastic reaction. The second model is ARCaP, where prostate cancer cells derived from the ascites fluid of a man with metastatic disease exhibited an Androgen- and estrogen-Repressed Prostate Cancer cell growth and tumor formation in either a hormone-deficient or a castrated environment. However, the growth of either the tumor cells in vitro or the tumors in vivo was suppressed by both estrogen and androgen. While the tumor cells expressed low levels of androgen receptor and prostate-specific antigen (PSA), they were highly metastatic when inoculated orthotopically. Distant metastases to a number of organs were detected including the liver, lung, kidney, and bone.",
author = "Chung, {L. W.K.} and Chinghai Kao and Sikes, {R. A.} and Zhau, {H. E.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1515/9783110807271.107",
language = "English (US)",
isbn = "3110161591",
pages = "107--114",
booktitle = "Molecular Biology of Prostate Cancer",
publisher = "de Gruyter",
address = "Germany",

}

TY - CHAP

T1 - Human prostate cancer progression models and therapeutic intervention

AU - Chung, L. W.K.

AU - Kao, Chinghai

AU - Sikes, R. A.

AU - Zhau, H. E.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Our laboratory has developed two cellular models of human prostate cancer progression. The LNCaP prostate cancer progression model is based upon the wellknown cellular interaction between human prostate or bone stromal cells and LNCaP cells in vivo. The marginally tumorigenic LNCaP cells acquired tumorigenic and metastatic potential upon cellular interaction with either prostate or bone fibroblasts. A subline termed C4-2 was observed to grow readily in castrated animals and acquired metastatic potential spreading from the primary tumor site to the lymph node, the seminal vesicles, and the axial skeleton, resulting in an intense osteoblastic reaction. The second model is ARCaP, where prostate cancer cells derived from the ascites fluid of a man with metastatic disease exhibited an Androgen- and estrogen-Repressed Prostate Cancer cell growth and tumor formation in either a hormone-deficient or a castrated environment. However, the growth of either the tumor cells in vitro or the tumors in vivo was suppressed by both estrogen and androgen. While the tumor cells expressed low levels of androgen receptor and prostate-specific antigen (PSA), they were highly metastatic when inoculated orthotopically. Distant metastases to a number of organs were detected including the liver, lung, kidney, and bone.

AB - Our laboratory has developed two cellular models of human prostate cancer progression. The LNCaP prostate cancer progression model is based upon the wellknown cellular interaction between human prostate or bone stromal cells and LNCaP cells in vivo. The marginally tumorigenic LNCaP cells acquired tumorigenic and metastatic potential upon cellular interaction with either prostate or bone fibroblasts. A subline termed C4-2 was observed to grow readily in castrated animals and acquired metastatic potential spreading from the primary tumor site to the lymph node, the seminal vesicles, and the axial skeleton, resulting in an intense osteoblastic reaction. The second model is ARCaP, where prostate cancer cells derived from the ascites fluid of a man with metastatic disease exhibited an Androgen- and estrogen-Repressed Prostate Cancer cell growth and tumor formation in either a hormone-deficient or a castrated environment. However, the growth of either the tumor cells in vitro or the tumors in vivo was suppressed by both estrogen and androgen. While the tumor cells expressed low levels of androgen receptor and prostate-specific antigen (PSA), they were highly metastatic when inoculated orthotopically. Distant metastases to a number of organs were detected including the liver, lung, kidney, and bone.

UR - http://www.scopus.com/inward/record.url?scp=85064807109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064807109&partnerID=8YFLogxK

U2 - 10.1515/9783110807271.107

DO - 10.1515/9783110807271.107

M3 - Chapter

SN - 3110161591

SN - 9783110161595

SP - 107

EP - 114

BT - Molecular Biology of Prostate Cancer

PB - de Gruyter

ER -